Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PALIPERIDONE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N05A, N05AX) — coverage varies; not interchangeable

  • Aripiprazole (Abilify Asimtufii): general benefit
  • Brexpiprazole (Rexulti): general benefit
  • Cariprazine (Vraylar): general benefit
  • Risperidone (Risperdal): general benefit, Not a benefit
  • Asenapine (Saphris): general benefit
  • Chlorpromazine (Teva-Chlorpromazine): general benefit, Not a benefit

17 more in the class list below

Invega · DIN 02300273 · 3mg · extended release tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Invega · DIN 02300273 Manufacturer: Janssen Inc.; listing date 2009-08-18 Health Canada: Marketed since 2007-10-02 · brand INVEGA · ATC N05AX13 PALIPERIDONE · form Tablet (extended-release) · route Oral · ingredients PALIPERIDONE 3 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Invega: Formulary list price $4.5570/unit (unit not stated in source; not the patient's cost)

Ministry pays: $4.5570 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78559 · Verify on the e-Formulary ↗ (DIN 02300273)

Source record
DIN 02300273: Invega Raw flags: sec3=Y Item: 281608245; group id 500; item number 1294; lccId None; manufacturer id JAN Source form: ER Tab; strength: 3mg Recorded listing: General benefit Source prices (unrounded): $4.5570; ministry $4.5570 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02300273 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78559
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02300273
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Invega · DIN 02300281 · 6mg · extended release tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Invega · DIN 02300281 Manufacturer: Janssen Inc.; listing date 2009-08-18 Health Canada: Marketed since 2007-10-02 · brand INVEGA · ATC N05AX13 PALIPERIDONE · form Tablet (extended-release) · route Oral · ingredients PALIPERIDONE 6 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Invega: Formulary list price $6.8160/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8160 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78560 · Verify on the e-Formulary ↗ (DIN 02300281)

Source record
DIN 02300281: Invega Raw flags: sec3=Y Item: 281608246; group id 500; item number 1295; lccId None; manufacturer id JAN Source form: ER Tab; strength: 6mg Recorded listing: General benefit Source prices (unrounded): $6.8160; ministry $6.8160 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02300281 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78560
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02300281
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Invega · DIN 02300303 · 9mg · extended release tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Invega · DIN 02300303 Manufacturer: Janssen Inc.; listing date 2009-08-18 Health Canada: Marketed since 2007-10-02 · brand INVEGA · ATC N05AX13 PALIPERIDONE · form Tablet (extended-release) · route Oral · ingredients PALIPERIDONE 9 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Invega: Formulary list price $9.0850/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.0850 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78561 · Verify on the e-Formulary ↗ (DIN 02300303)

Source record
DIN 02300303: Invega Raw flags: sec3=Y Item: 281608247; group id 500; item number 1296; lccId None; manufacturer id JAN Source form: ER Tab; strength: 9mg Recorded listing: General benefit Source prices (unrounded): $9.0850; ministry $9.0850 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02300303 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78561
Shortage status: anticipated shortage (last updated 2026-09-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02300303
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PALIPERIDONE PALMITATE

Form:

8 of 8 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N05A, N05AX) — coverage varies; not interchangeable

  • Aripiprazole (Abilify Asimtufii): general benefit
  • Brexpiprazole (Rexulti): general benefit
  • Cariprazine (Vraylar): general benefit
  • Risperidone (Risperdal): general benefit, Not a benefit
  • Asenapine (Saphris): general benefit
  • Chlorpromazine (Teva-Chlorpromazine): general benefit, Not a benefit

17 more in the class list below

Invega Sustenna · DIN 02354217 · 50mg · injection, pre-filled syringe

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Invega Sustenna · DIN 02354217 Manufacturer: Janssen Inc.; listing date 2012-01-19 Health Canada: Marketed since 2010-07-21 · brand INVEGA SUSTENNA · ATC N05AX13 PALIPERIDONE · form Suspension (extended-release) · route Intramuscular · ingredients PALIPERIDONE (PALIPERIDONE PALMITATE) 50 MG/0.5ML · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Invega Sustenna: Formulary list price $327.4500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $327.4500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83941 · Verify on the e-Formulary ↗ (DIN 02354217)

Source record
DIN 02354217: Invega Sustenna Raw flags: sec3=Y Item: 281608307; group id 501; item number 1297; lccId None; manufacturer id JAN Source form: Inj Pref Syr; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $327.4500; ministry $327.4500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02354217 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83941 Therapeutic Notes (formulary) For the treatment of schizophrenia or schizoaffective disorders in patients who have: A history of non-adherence; AND one of the following: (a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR (b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02354217
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Invega Sustenna · DIN 02354225 · 75mg · injection, pre-filled syringe

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Invega Sustenna · DIN 02354225 Manufacturer: Janssen Inc.; listing date 2012-01-19 Health Canada: Marketed since 2010-07-21 · brand INVEGA SUSTENNA · ATC N05AX13 PALIPERIDONE · form Suspension (extended-release) · route Intramuscular · ingredients PALIPERIDONE (PALIPERIDONE PALMITATE) 75 MG/0.75ML · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Invega Sustenna: Formulary list price $491.1800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $491.1800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83942 · Verify on the e-Formulary ↗ (DIN 02354225)

Source record
DIN 02354225: Invega Sustenna Raw flags: sec3=Y Item: 281608308; group id 501; item number 1298; lccId None; manufacturer id JAN Source form: Inj Pref Syr; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $491.1800; ministry $491.1800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02354225 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83942 Therapeutic Notes (formulary) For the treatment of schizophrenia or schizoaffective disorders in patients who have: A history of non-adherence; AND one of the following: (a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR (b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02354225
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Invega Sustenna · DIN 02354233 · 100mg · injection, pre-filled syringe

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Invega Sustenna · DIN 02354233 Manufacturer: Janssen Inc.; listing date 2012-01-19 Health Canada: Marketed since 2010-07-21 · brand INVEGA SUSTENNA · ATC N05AX13 PALIPERIDONE · form Suspension (extended-release) · route Intramuscular · ingredients PALIPERIDONE (PALIPERIDONE PALMITATE) 100 MG/1ML · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Invega Sustenna: Formulary list price $544.4400/unit (unit not stated in source; not the patient's cost)

Ministry pays: $544.4400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83943 · Verify on the e-Formulary ↗ (DIN 02354233)

Source record
DIN 02354233: Invega Sustenna Raw flags: sec3=Y Item: 281608309; group id 501; item number 1299; lccId None; manufacturer id JAN Source form: Inj Pref Syr; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $544.4400; ministry $544.4400 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02354233 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83943 Therapeutic Notes (formulary) For the treatment of schizophrenia or schizoaffective disorders in patients who have: A history of non-adherence; AND one of the following: (a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR (b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02354233
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Invega Sustenna · DIN 02354241 · 150mg · injection, pre-filled syringe

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Invega Sustenna · DIN 02354241 Manufacturer: Janssen Inc.; listing date 2012-01-19 Health Canada: Marketed since 2010-07-21 · brand INVEGA SUSTENNA · ATC N05AX13 PALIPERIDONE · form Suspension (extended-release) · route Intramuscular · ingredients PALIPERIDONE (PALIPERIDONE PALMITATE) 150 MG/1.5ML · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Invega Sustenna: Formulary list price $725.9100/unit (unit not stated in source; not the patient's cost)

Ministry pays: $725.9100 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83944 · Verify on the e-Formulary ↗ (DIN 02354241)

Source record
DIN 02354241: Invega Sustenna Raw flags: sec3=Y Item: 281608310; group id 501; item number 1300; lccId None; manufacturer id JAN Source form: Inj Pref Syr; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $725.9100; ministry $725.9100 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02354241 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83944 Therapeutic Notes (formulary) For the treatment of schizophrenia or schizoaffective disorders in patients who have: A history of non-adherence; AND one of the following: (a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR (b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02354241
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Invega Trinza · DIN 02455943 · 175mg/0.875mL · injection suspension-pre-filled syringe

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Invega Trinza · DIN 02455943 Manufacturer: Janssen Inc.; listing date 2018-03-29 Health Canada: Marketed since 2016-07-25 · brand INVEGA TRINZA · ATC N05AX13 PALIPERIDONE · form Suspension (extended-release) · route Intramuscular · ingredients PALIPERIDONE (PALIPERIDONE PALMITATE) 175 MG/0.875ML · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Invega Trinza: Formulary list price $953.7300/unit (unit not stated in source; not the patient's cost)

Ministry pays: $953.7300 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94281 · Verify on the e-Formulary ↗ (DIN 02455943)

Source record
DIN 02455943: Invega Trinza Raw flags: sec3=Y Item: 281608334; group id 501; item number 1301; lccId None; manufacturer id JAN Source form: Inj Susp-Pref Syr; strength: 175mg/0.875mL Recorded listing: General benefit Source prices (unrounded): $953.7300; ministry $953.7300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02455943 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94281 Therapeutic Notes (formulary) For the treatment of schizophrenia or schizoaffective disorders in patients who have: A history of non-adherence AND One of the following: a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents. AND Adequate treatment of using 1-month paliperidone palmitate prolonged-release injectable suspension has been established for at least four months.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02455943
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Invega Trinza · DIN 02455986 · 263mg/1.315mL · injection suspension-pre-filled syringe

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Invega Trinza · DIN 02455986 Manufacturer: Janssen Inc.; listing date 2018-03-29 Health Canada: Marketed since 2016-07-25 · brand INVEGA TRINZA · ATC N05AX13 PALIPERIDONE · form Suspension (extended-release) · route Intramuscular · ingredients PALIPERIDONE (PALIPERIDONE PALMITATE) 263 MG/1.315ML · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Invega Trinza: Formulary list price $1430.6100/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1430.6100 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94284 · Verify on the e-Formulary ↗ (DIN 02455986)

Source record
DIN 02455986: Invega Trinza Raw flags: sec3=Y Item: 281608335; group id 501; item number 1302; lccId None; manufacturer id JAN Source form: Inj Susp-Pref Syr; strength: 263mg/1.315mL Recorded listing: General benefit Source prices (unrounded): $1430.6100; ministry $1430.6100 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02455986 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94284 Therapeutic Notes (formulary) For the treatment of schizophrenia or schizoaffective disorders in patients who have: A history of non-adherence AND One of the following: a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents. AND Adequate treatment of using 1-month paliperidone palmitate prolonged-release injectable suspension has been established for at least four months.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02455986
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Invega Trinza · DIN 02455994 · 350mg/1.75mL · injection suspension-pre-filled syringe

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Invega Trinza · DIN 02455994 Manufacturer: Janssen Inc.; listing date 2018-03-29 Health Canada: Marketed since 2016-07-25 · brand INVEGA TRINZA · ATC N05AX13 PALIPERIDONE · form Suspension (extended-release) · route Intramuscular · ingredients PALIPERIDONE (PALIPERIDONE PALMITATE) 350 MG/1.75ML · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Invega Trinza: Formulary list price $1430.6100/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1430.6100 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94285 · Verify on the e-Formulary ↗ (DIN 02455994)

Source record
DIN 02455994: Invega Trinza Raw flags: sec3=Y Item: 281608336; group id 501; item number 1303; lccId None; manufacturer id JAN Source form: Inj Susp-Pref Syr; strength: 350mg/1.75mL Recorded listing: General benefit Source prices (unrounded): $1430.6100; ministry $1430.6100 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02455994 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94285 Therapeutic Notes (formulary) For the treatment of schizophrenia or schizoaffective disorders in patients who have: A history of non-adherence AND One of the following: a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents. AND Adequate treatment of using 1-month paliperidone palmitate prolonged-release injectable suspension has been established for at least four months.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02455994
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Invega Trinza · DIN 02456001 · 525mg/2.625mL · injection suspension-pre-filled syringe

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Invega Trinza · DIN 02456001 Manufacturer: Janssen Inc.; listing date 2018-03-29 Health Canada: Marketed since 2016-07-25 · brand INVEGA TRINZA · ATC N05AX13 PALIPERIDONE · form Suspension (extended-release) · route Intramuscular · ingredients PALIPERIDONE (PALIPERIDONE PALMITATE) 525 MG/2.625ML · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Invega Trinza: Formulary list price $1907.4900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1907.4900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94286 · Verify on the e-Formulary ↗ (DIN 02456001)

Source record
DIN 02456001: Invega Trinza Raw flags: sec3=Y Item: 281608337; group id 501; item number 1304; lccId None; manufacturer id JAN Source form: Inj Susp-Pref Syr; strength: 525mg/2.625mL Recorded listing: General benefit Source prices (unrounded): $1907.4900; ministry $1907.4900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456001 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94286 Therapeutic Notes (formulary) For the treatment of schizophrenia or schizoaffective disorders in patients who have: A history of non-adherence AND One of the following: a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents. AND Adequate treatment of using 1-month paliperidone palmitate prolonged-release injectable suspension has been established for at least four months.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456001
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

RISPERIDONE

· 82 products · Listed, not a benefit (12), General benefit (70) · strengths: 1mg/mL, 0.5mg, 1mg, 2mg, 3mg, 4mg, 25mg, 37.5mg, 50mg, 0.25mg · O/L, Orally Disintegrating Tab, Pd for Inj-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab

LURASIDONE HYDROCHLORIDE

· 38 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4), General benefit (33), Listed, not a benefit (1) · strengths: 20mg, 40mg, 60mg, 80mg, 120mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 20 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: schizophrenia, schizophrenia and related psychotic disorders
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, ZIPRASIDONE HCL MONOHYDRATE ARIPIPRAZOLE · General benefit 1 INDICATIONS ABILIFY (aripiprazole) is indicated for:  the treatment of schizophrenia and related psychotic disorders in adults. PM: https://pdf.hres.ca/dpd_pm/00060025.PDF; date February 11, 2021; DIN 02322374; fetched 2026-09-10 Product monograph  the treatment of schizophrenia and related psychotic disorders in adults. In controlled clinical trials, ABILIFY was found to improve both positive and negative symptoms. ABILIFY has been shown to be more effective than placebo in maintaining clinical improvement for up to 26 weeks in adults. PM: https://pdf.hres.ca/dpd_pm/00060025.PDF; date February 11, 2021; DIN 02322374; fetched 2026-09-10 Product monograph ASENAPINE · General benefit INDICATIONS AND CLINICAL USE Adults: Schizophrenia SAPHRIS® (asenapine) sublingual tablet is indicated for the treatment of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00060860.PDF; date April 27, 2021; DIN 02374803; fetched 2026-09-10 Product monograph BREXPIPRAZOLE · General benefit 1 INDICATIONS REXULTI (brexpiprazole) is indicated for: • treatment of schizophrenia in adults. PM: https://pdf.hres.ca/dpd_pm/00074327.PDF; date February 16, 2017; DIN 02461749; fetched 2026-09-10 Product monograph • treatment of schizophrenia in adults. In clinical trials, REXULTI was found to significantly improve both positive and negative symptoms. PM: https://pdf.hres.ca/dpd_pm/00074327.PDF; date February 16, 2017; DIN 02461749; fetched 2026-09-10 Product monograph CARIPRAZINE · General benefit 1 INDICATIONS Schizophrenia VRAYLAR (cariprazine) is indicated for: • the treatment of schizophrenia in adults. PM: https://pdf.hres.ca/dpd_pm/00074842.PDF; date MAR 06, 2024; DIN 02526794; fetched 2026-09-10 Product monograph • the treatment of schizophrenia in adults. In controlled clinical trials, VRAYLAR was found to improve both positive and negative symptoms. PM: https://pdf.hres.ca/dpd_pm/00074842.PDF; date MAR 06, 2024; DIN 02526794; fetched 2026-09-10 Product monograph OLANZAPINE · General benefit (99), Off-Formulary Interchangeable, not an ODB benefit (17) Indications ZYPREXA, ZYPREXA ZYDIS (oral olanzapine) is indicated for • the acute and maintenance treatment of schizophrenia and related psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00085079.PDF; date 2026-06-16; DIN 02229250; fetched 2026-09-10 Product monograph RISPERIDONE · Listed, not a benefit (12), General benefit (70) 1 INDICATIONS Adults Schizophrenia pms-RISPERIDONE (risperidone) is indicated for the acute treatment and maintenance treatment of schizophrenia and related psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00062538.PDF; date August 13, 2021; DIN 02252007; fetched 2026-09-10 Product monograph ZIPRASIDONE HCL MONOHYDRATE · General benefit 1 INDICATIONS  Schizophrenia ZELDOX (ziprasidone) is indicated for the treatment of schizophrenia and related psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00072509.PDF; date SEP 15, 2023; DIN 02298597; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS INVEGA® (paliperidone) is indicated for the treatment of schizophrenia and related psychotic disorders. In controlled clinical trials, INVEGA® was found to improve the symptoms of schizophrenia, including positive and negative symptoms. 1.1 Pediatrics Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of INVEGA® in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use and its use is not recommended. See WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics. 1.2 Geriatrics Geriatrics (> 65 years of age): Elderly patients with dementia treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. INVEGA® is not indicated for the treatment of elderly patients with dementia. See SERIOUS WARNINGS AND PRECAUTIONS BOX and WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics. https://pdf.hres.ca/dpd_pm/00059282.PDF PM date: December 17, 2020 Source product: INVEGA; DIN 02300273; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS Adults INVEGA SUSTENNA® (paliperidone palmitate prolonged-release injectable suspension) is indicated for: • the treatment of schizophrenia. In controlled clinical trials, Invega Sustenna was found to improve the symptoms of schizophrenia, including positive and negative symptoms. • maintenance treatment of schizoaffective disorder. The efficacy of Invega Sustenna in maintaining symptomatic control for up to 15 months was demonstrated in a double- blind, placebo controlled clinical trial of adult patients with schizoaffective disorder who were first stabilized on Invega Sustenna during 6 months of open-label treatment. 1.1 Pediatrics Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of Invega Sustenna in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use and its use is not recommended. See 7.1.3 Pediatrics. 1.2 Geriatrics Geriatrics (> 65 years of age): Elderly patients with dementia treated with atypical antipsychotic drugs are at an increased risk of death… https://pdf.hres.ca/dpd_pm/00072646.PDF PM date: June 30, 2010 Source product: INVEGA SUSTENNA; DIN 02354217; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.